|
Dr. Reddy's Laboratories, is a multinational pharmaceutical company based in Hyderabad, Telangana, India. The company was founded by Anji Reddy, who previously worked in the mentor institute, Indian Drugs and Pharmaceuticals Limited, of Hyderabad, India.〔http://www.drreddys.com/media/pdf/HBL-Pharmas-Free-Radical-mar-23.pdf〕 Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology products. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration (FDA). By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. In 2014, Dr. Reddy Laboratories was listed among 1200 of India's most trusted brands according to the Brand Trust Report 2014, a study conducted by Trust Research Advisory, a brand analytics company. By 2007, Dr. Reddy's had six FDA plants producing active pharmaceutical ingredients in India and seven FDA-inspected and ISO 9001 (quality) and ISO 14001 (environmental management) certified plants making patient-ready medications – five of them in India and two in the UK.〔('' Dr Reddy's Laboratories 2007-2012'' – MarketReports.com 2007 life sciences research report, Technology Networks, Sudbury, Essex, UK ).Accessed: 2007-08-22.〕 In 2010, the family-controlled Dr Reddy's denied〔(''Dr. Reddy's Laboratories Limited Says Not To Sell Any Business-DJ'', Reuters news agency, 23 March 2010 ).Accessed 2 October 2010.〕 that it was in talks to sell its generics business in India to US pharmaceutical giant Pfizer,〔( ''Pfizer in talks to buy DRL’s formulations business in India'', NDTV, New Delhi, 23 February 2010 ).Accessed 2 October 2010.〕 which had been suing the company for alleged patent infringement after Dr Reddy's announced that it intended to produce a generic version of atorvastatin, marketed by Pfizer as Lipitor, an anti-cholesterol medication.〔(''Dr Reddy's develops generic version of Pfizer's Lipitor'', Business Standard, New Delhi and Mumbai, 7 November 2009 ).Accessed 2 October 2010.〕〔( ''Pfizer Sues Dr Reddy’s Over Cholesterol Drug ‘Lipitor’ '', Stock Watch, Mumbai, 12 November 2009 ).Accessed 2 October 2010.〕 Reddy's was already linked to UK pharmaceuticals multinational Glaxo Smithkline.〔(''AstraZeneca Partners with India's Torrent Pharmaceuticals'', Pharmaceutical Technology, Iselin, NJ and Chester UK ).Accessed 2 October 2010.〕 ==Company history== Dr. Reddy's originally launched in 1984 producing active pharmaceutical ingredients. In 1986, Reddy's started operations on branded formulations. Within a year Reddy's had launched Norilet, the company's first recognized brand in India. Soon, Dr. Reddy's obtained another success with Omez, its branded omeprazole – ulcer and reflux oesophagitis medication – launched at half the price of other brands on the Indian market at that time. Within a year, Reddy's became the first Indian company to export the active ingredients for pharmaceuticals to Europe. In 1987, Reddy's started to transform itself from a supplier of pharmaceutical ingredients to other manufacturers into a manufacturer of pharmaceutical products. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Dr. Reddy's Laboratories」の詳細全文を読む スポンサード リンク
|